Chronic idiopathic myelofibrosis (CIMF)

Chronic idiopathic myelofibrosis (CIMF) is a rare type of blood cancer that affects the bone marrow. In this condition, the bone marrow is replaced with scar tissue, which can cause problems with the production of blood cells. CIMF is considered an idiopathic disorder because the cause of the disease is unknown.

Symptoms of CIMF

Symptoms of CIMF can vary but may include fatigue, weakness, shortness of breath, fever, night sweats, and abdominal pain. In some cases, CIMF may progress to acute myeloid leukemia, a more aggressive form of blood cancer.

Diagnose and treatment of CIMF

The diagnosis of CIMF is usually made through a combination of blood tests, bone marrow biopsy, and imaging studies.

Treatment for CIMF depends on the severity of the disease and the symptoms present. Options may include medications to help control symptoms, blood transfusions to correct anemia, and in some cases, stem cell transplantation. In addition, clinical trials may be available for individuals with CIMF to test new treatments.

Unfortunately, CIMF is a progressive disease and there is no cure. The target of treatment is to manage symptoms and slow the progression of CIMF disease. People with CIMF are encouraged to work with their healthcare providers to develop a comprehensive treatment plan that takes into account their individual needs and preferences.

In addition, it’s important for people with CIMF to practice healthy lifestyle habits, such as getting regular exercise, eating a nutritious diet, and avoiding smoking and excessive alcohol consumption. Emotional support and counseling may also be beneficial for individuals and their families coping with the challenges of CIMF.

Medicines used for CIMF


  • Gefitinib
  • Lapatinib
  • Erlotinib
  • Pazopanib
  • Sorafenib
  • Imatinib mesylate
  • Sunitinib
  • Crizotinib
  • Dasatinib
  • Axitinib
  • Regorafenib
  • Ruxolitinib
  • Nilotinib
  • Afatinib dimaleate
  • Osimertinib
  • Nintedanib
  • Ceritinib
  • Lenvatinib
  • Alectinib
  • Lorlatinib
  • Bosutinib
  • Abemaciclib
  • Cabozantinib
  • Tepotinib